title: Reversal of temporal and spatial heterogeneities in tumor perfusion identifies the tumor vascular tone as a tunable variable to improve drug delivery.
abstract: Maturation of tumor vasculature involves the recruitment of pericytes that protect the endothelial tubes from a variety of stresses, including antiangiogenic drugs. Mural cells also provide mature tumor blood vessels with the ability to either relax or contract in response to substances present in the tumor microenvironment. The observed cyclic alterations in tumor blood flow and the associated deficit in chemotherapeutic drug delivery could in part arise from this vasomodulatory influence. To test this hypothesis, we focused on endothelin-1 (ET-1), which, besides its autocrine effects on tumor cell growth, is a powerful vasoconstrictor. We first document that an ET(A) receptor antagonist induced relaxation of microdissected tumor arterioles and selectively and quantitatively increased tumor blood flow in experimental tumor models. We then combined dye staining of functional vessels, fluorescent microsphere-based mapping, and magnetic resonance imaging to identify heterogeneities in tumor blood flow and to examine the reversibility of such phenomena. Data from all these techniques concurred to show that administration of an ET(A) receptor antagonist could reduce the extent of underperfused tumor areas, proving the key role of vessel tone variations in tumor blood flow heterogeneity. We also provide evidence that ET(A) antagonist administration could, despite an increase in tumor interstitial fluid pressure, improve access of cyclophosphamide to the tumor compartment and significantly influence tumor growth. In conclusion, tumor endogenous ET-1 production participates largely in the temporal and spatial variations in tumor blood flow. ET(A) antagonist administration may wipe out such heterogeneities, thus representing an adjuvant strategy that could improve the delivery of conventional chemotherapy to tumors.
authors.affiliation: Unit of Pharmacology and Therapeutics, UCL Medical School, 53 Ave E. Mounier, B-1200 Brussels, Belgium.
authors.forename: Philippe
authors.initials: P
authors.lastname: Martinive
authors.forename: Julie
authors.initials: J
authors.lastname: De Wever
authors.forename: Caroline
authors.initials: C
authors.lastname: Bouzin
authors.forename: Christine
authors.initials: C
authors.lastname: Baudelet
authors.forename: Pierre
authors.initials: P
authors.lastname: Sonveaux
authors.forename: Vincent
authors.initials: V
authors.lastname: Grégoire
authors.forename: Bernard
authors.initials: B
authors.lastname: Gallez
authors.forename: Olivier
authors.initials: O
authors.lastname: Feron
mesh_terms: D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology; D017209:Apoptosis; D001160:Arterioles / Q000187:drug effects / Q000473:pathology; D001783:Blood Flow Velocity / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D001808:Blood Vessels / Q000187:drug effects / Q000473:pathology; D003520:Cyclophosphamide / Q000494:pharmacology; D016503:Drug Delivery Systems; D065130:Endothelin A Receptor Antagonists; D019332:Endothelin-1 / Q000494:pharmacology*; D020287:In Situ Nick-End Labeling; D008279:Magnetic Resonance Imaging; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D009126:Muscle Relaxation / Q000187:drug effects; D009369:Neoplasms / Q000098:blood supply* / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000188:drug therapy*
chemical_list: D018906:Antineoplastic Agents, Alkylating; D065130:Endothelin A Receptor Antagonists; D019332:Endothelin-1; D003520:Cyclophosphamide